<DOC>
	<DOC>NCT00090090</DOC>
	<brief_summary>To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).</brief_summary>
	<brief_title>Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<mesh_term>Elsamicin A</mesh_term>
	<criteria>Relapsed or Refractory mantle cell lymphoma and/or CLL/SLL except Burkitt's, Burkitt's like or HIVassociated lymphoma at least one prior cytotoxic chemotherapy regimens measurable disease adequate bone marrow, liver and kidney function ECOG PS 02 prior treatment with elsamitrucin prior chemo, antibody or radiotherapy for NHL within 28 days prior to start to treatment HIV positive or known AIDS syndrome uncontrolled medical disease or psychiatric condition/s</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>